Table 4.
Circulating HSPA1A levels (ng/mL) according to genotype in the general population and stratified by risk groups
| AA | Pa | AC | Pa | CC | Pb | Pa | Pc | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| General population (N = 146) | General population (N = 207) | General population (N = 90) | |||||||||||
| 1.18 (0.00–7.54) | 1.21 (0.05–29.55) | 1.27 (0.28–5.23) | NS | ||||||||||
| G0 (N = 74) | G1 (N = 58) | G2 (N = 14) | G0 (N = 104) | G1 (N = 75) | G2 (N = 28) | G0 (N = 56) | G1 (N = 25) | G2 (N = 9) | |||||
| 1.24 (0.19–4.22) | 1.25 (0.0–7.54) | 1.02 (0.31–3.48) | NS (P = 0.21) | 1.21 (0.23–29.55) | 1.46 (0.10–6.76) | 1.14 (0.05–3.90) | NS (P = 0.4) | 1.42 (0.33–3.15) | 1.15 (0.69–5.23) | 1.09 (0.28–1.76) | NS (P = 0.13) | P = 0.028 | |
Data are expressed as median (range)
aP: differences according to genotypes, the grouping variable being vascular risk (Kruskal–Wallis test, P = NS)
bP: differences according to genotype in the general population (Kruskal–Wallis test, P = NS)
cP: differences according to vascular risk group. Serum HSPA1A concentration was significantly lower in the group of patients with established atherosclerosis disease than in the other two groups regardless of the genotype involved (Kruskal–Wallis test)